mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial

Published:2022-02 Issue:4 Volume:10 Page:171-171
ISSN:2305-5839
Container-title:Annals of Translational Medicine
language:
Short-container-title:Ann Transl Med

Author:

Shen Cailu,Hu Huabin,Cai Yue,Ling Jiayu,Zhang Jianwei,Wu Zehua,Xie Xiaoyu,Huang Meijin,Wang Hui,Kang Liang,Lan Ping,Wu Xiaojian,Liu Guangjian,Wan Yunle,Zhou Zhiyang,Huang Yan,Li Fangqian,Wang Huaiming,Ma Tenghui,Luo Shuangling,Cai Yonghua,Shi Lishuo,Deng Yanhong

Publisher

AME Publishing Company

Subject

General Medicine

Link

https://atm.amegroups.com/article/download/89891/pdf

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Combination Therapy for RAS-related Colorectal Cancer;PROG BIOCHEM BIOPHYS;2023

2. Capecitabine maintenance therapy in metastatic colorectal cancer patients with no evidence of disease: CAMCO trial;Future Oncology;2023-09

3. Research Progress of Conversion Therapy in Colorectal Cancer Liver Metastasis;Advances in Clinical Medicine;2023

4. Clinical strategy of conversion therapy and surgical treatment for liver metastases from colorectal cancer;World Chinese Journal of Digestology;2022-10-28

5. BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies;Cancers;2022-08-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP